Endothelin-1 in hypertensive patients with ischemic heart disease

Area of Science:

• Cardiology
• Vascular Biology
• Hypertension Research

Background:

• Endothelin-1 (ET-1) is a potent vasoconstrictor implicated in cardiovascular diseases.
• Hypertension is a major risk factor for ischemic heart disease.
• The role of ET-1 in myocardial ischemia, particularly in hypertensive individuals, requires further elucidation.

Purpose of the Study:

• To evaluate if transient myocardial ischemia induced by dipyridamole stress testing correlates with changes in plasma endothelin-1 levels.
• To compare these changes between normotensive and hypertensive patients, with and without stable angina.

Main Methods:

• Retrospective analysis of 40 patients undergoing high-dose Dipyridamole Echocardiographic-Scintigraphic (DES) testing.
• Four groups were analyzed: control normotensives, essential hypertensives (negative DES), essential hypertensives with stable angina, and normotensives with stable angina (positive DES).
• Plasma ET-1 levels were measured at baseline and post-dipyridamole stress.

Main Results:

• A significant increase in plasma ET-1 levels was observed post-DES in hypertensive patients with stable angina (16.50 ± 4.19 pg/ml, p < 0.001 vs. baseline 9.05 ± 1.37 pg/ml).
• A minor, though significant, increase was noted in normotensive patients with stable angina (8.3 ± 1.75 pg/ml, p < 0.01 vs. baseline 6.74 ± 0.61 pg/ml).
• No significant changes in ET-1 levels were found in control normotensives or essential hypertensives without angina.

Conclusions:

• The study indicates a strong association between dipyridamole-induced myocardial ischemia in hypertensive patients and elevated endothelin-1 plasma levels.
• Endothelin-1 appears to be involved in the pathophysiology of hypertension-related ischemic heart disease.
• These findings highlight the potential clinical significance of ET-1 in managing hypertensive patients with ischemic symptoms.